A surprisingly high rate of nonconvulsive seizures and status epilepticus is found during continuous EEG monitoring in critically ill patients. A recent analysis of data regarding hospitalization and ...

Most seizures last less than 5 minutes. But sometimes they don’t stop there – or they come one after the other, giving the person suffering from them no chance to recover. “Status epilepticus” ...

NASHVILLE, Tennessee ― New research shows stark racial and ethnic discrepancies in healthcare outcomes for patients with status epilepticus (SE). Investigators found that among Black patients with SE, ...

Intravenous valproate, levetiracetam, and fosphenytoin stopped status epilepticus that was resistant to initial treatment with lorazepam in approximately half the patients and did not differ ...

Status epilepticus is a condition that is characterized by repeated seizures and is a medical emergency. Treatment is usually with a Benzodiazepine such as Diazepam or Lorazepam etc. There have been ...

Patients treated for more than 28 days had a higher chance of status epilepticus cessation, but also a high risk of moderate to severe disability at discharge, according to one study. In a ...

Sustained, intensive therapy with two antiglutamatergic drugs is superior to standard aggressive treatment for postanoxic super-refractory status epilepticus (SRSE), new research suggests. In a ...

Epilepsy affects over 70 million people worldwide, and a significant portion of patients suffer from drug-resistant epilepsy (DRE), where standard medications fail. Beyond the seizures themselves, ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders ...

MIDDLETON, Wis., Dec. 3, 2025 /PRNewswire/ -- Natus Medical Incorporated announced the electrographic status epilepticus diagnosis capability of its BrainWatch point-of-care EEG solution, featuring ...

RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced ...